FDA Panel Friday for Horizon’s teprotumumab for thyroid eye disease
The FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee will meet on Friday, December 13, to review and discuss Horizon Therapeutics’ (HZNP+0.8%) marketing application for lead drug teprotumumab for thyroid eye disease.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.